146 related articles for article (PubMed ID: 33529909)
1. IgE antibodies to hepatitis C virus core and nonstructural antigens in chronic hepatitis C patients before and after antiviral treatment.
Silva JPCG; Jesus LS; Isabel Schinoni M; Oliveira IS; Atta MLBS; Atta AM
Int Immunopharmacol; 2021 Apr; 93():107405. PubMed ID: 33529909
[TBL] [Abstract][Full Text] [Related]
2. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
Caetano J; Martinho A; Paiva A; Pais B; Valente C; Luxo C
J Virol; 2008 Aug; 82(15):7567-77. PubMed ID: 18480446
[TBL] [Abstract][Full Text] [Related]
3. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
Chu CM; Sheen IS; Liaw YF
Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
5. Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients.
Feng B; Yang RF; Zhang HY; Luo BF; Kong FY; Rao HY; Jin Q; Cong X; Wei L
Braz J Infect Dis; 2015; 19(4):390-8. PubMed ID: 26100438
[TBL] [Abstract][Full Text] [Related]
6. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
[TBL] [Abstract][Full Text] [Related]
7. Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.
Burbelo PD; Kovacs JA; Ching KH; Issa AT; Iadarola MJ; Murphy AA; Schlaak JF; Masur H; Polis MA; Kottilil S
J Infect Dis; 2010 Sep; 202(6):894-8. PubMed ID: 20684729
[TBL] [Abstract][Full Text] [Related]
8. Detection of specific antibodies to HCV-ARF/CORE+1 protein in patients treated with pegylated interferon plus ribavirin.
Karamitros T; Kakkanas A; Katsoulidou A; Sypsa V; Dalagiorgou G; Mavromara P; Hatzakis A
J Viral Hepat; 2012 Mar; 19(3):182-8. PubMed ID: 22329372
[TBL] [Abstract][Full Text] [Related]
9. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus nonstructural protein specific T cells are associated with virological responses to combination therapy in chronic HCV patients.
Zhang Y; Liu Y; Zhao Y; Shi L; Ma L; Yan H; Wu H; Wei L; Dong T; Chen X
Liver Int; 2012 Jan; 32(1):102-9. PubMed ID: 22098382
[TBL] [Abstract][Full Text] [Related]
11. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
[TBL] [Abstract][Full Text] [Related]
12. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kuzuya T; Honda T; Hayashi K; Nakano I; Katano Y; Goto H
Clin Infect Dis; 2005 Mar; 40(6):e49-54. PubMed ID: 15736006
[TBL] [Abstract][Full Text] [Related]
13. Quantitative antibody responses to structural (Core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood.
Beld M; Penning M; van Putten M; Lukashov V; van den Hoek A; McMorrow M; Goudsmit J
Hepatology; 1999 Apr; 29(4):1288-98. PubMed ID: 10094977
[TBL] [Abstract][Full Text] [Related]
14. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.
Maylin S; Martinot-Peignoux M; Ripault MP; Moucari R; Cardoso AC; Boyer N; Giuily N; Castelnau C; Pouteau M; Asselah T; Nicolas-Chanoine MH; Marcellin P
Liver Int; 2009 Apr; 29(4):511-7. PubMed ID: 19076273
[TBL] [Abstract][Full Text] [Related]
15. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
Pillai V; Lee WM; Thiele DL; Karandikar NJ
J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
[TBL] [Abstract][Full Text] [Related]
18. Evidence for immune activation in patients with residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin.
Radkowski M; Opoka-Kegler J; Cortes KC; Bukowska-Ośko I; Perlejewski K; Pawełczyk A; Laskus T
J Gen Virol; 2014 Sep; 95(Pt 9):2004-2009. PubMed ID: 24920726
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C.
Hempel G; Galle PR; Löhr HF
J Med Virol; 2001 Jul; 64(3):340-9. PubMed ID: 11424124
[TBL] [Abstract][Full Text] [Related]
20. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
